ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
aTYR PHARMA INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.17−0.00 (-1.32%)
Close on Oct 19, 2026
- Market cap
- $16.84M
- P/E (TTM)
- –
- Dividend yield
- –
aTYR PHARMA INC revenue by segment
By business segment
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue [Member] | $200.00K | $200.00K | $400.00K | $10.00M | – | $422.00K | 105.3% | 0.0% |
| License Revenues [Member] | – | – | – | – | $10.46M | $422.00K | – | – |
| License and Collaboration Revenues [Member] | – | – | – | $10.39M | $10.46M | – | – | – |
| Additional Collaboration Revenue [Member] | – | – | $400.00K | $400.00K | – | – | – | – |
By region
From the segment and revenue-disaggregation notes of aTYR PHARMA's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.